Structure via PubChem · Public domain (PubChem)
relebactam
Sign in to saveAlso known as relebactam anhydrous, Relebactam anhydrous
Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio by Merck).
In the Vinony graph
Within Vinony's link graph, relebactam is referenced by 186 other articles, and connects out to antibiotic, digital object identifier and chemical formula.
Vinony files it under 4-Piperidinyl compounds, Antibiotics and Beta-lactamase inhibitors.
Its subject is documented across 6 Wikipedia language editions.
Chemical data
- Formula
- C12H20N4O6S
- Molecular weight
- 348.38 g/mol
- IUPAC name
- [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
- SMILES
- C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
- InChIKey
- SMOBCLHAZXOKDQ-ZJUUUORDSA-N
- XLogP
- -3.6
- Polar surface area
- 137 Ų
- H-bond donors
- 3
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- parenteral
via ChEMBL · EBI
Research
659 papers- Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.Drugs · 2021
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
- Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.Life (Basel, Switzerland) · 2024
- Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel, Switzerland) · 2025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 348.11
Show 5 more facts
- chemical formula
- C₁₂H₂₀N₄O₆S
- canonical SMILES
- C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
- subject has role
- beta-lactamase inhibitors
- isomeric SMILES
- C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
- Commons category
- Relebactam
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio by Merck).
== See also == Avibactam
Excerpted from Wikipedia’s “relebactam” article, available under the CC BY-SA 4.0 licence.